Here at the Janssen Health Policy Centre
our mission is to raise awareness on issues impacting healthcare policy, build
consensus through dialogue, and shape recommendations for future policies

Report-23/12/2013
Pharma's New Productivity Challenge Perspectives from Europe

This latest PharmaFutures report summarises the findings of research and discussions about the European pharmaceuticals markets undertaken between November 2011 and May 2012. Focus is on the relationship between pharmaceutical companies, investors and health systems and the question how to maintain a sustainable pharmaceutical industry in Europe.

download
Report-14/11/2013
Pathways to Value: Pharma in a changing world

This PharmaFutures dialogue extends the analysis of an earlier report, opening up the conversation to include payers, regulators and other societal and government experts as well as assessing new trends in reimbursement, innovation and productivity. The conclusions from this dialogue can be found in: “Pathways to Value: Pharma in a Changing World”.

download

Pathways to Value: Pharma in a changing world

Download the report

The latest PharmaFutures dialogue extends the analysis of its most recent report, opening up the conversation to include payers, regulators and other societal and government experts as well as assessing new trends in reimbursement, innovation and productivity. The conclusions from the PharmaFutures dialogue can be found in the new report: “Pathways to Value: Pharma in a Changing World” published in June 2013. 

Janssen is an industry participants in the PharmaFutures dialogue and our EMEA Group Company Chairman, Jane Griffiths, is a member of the PharmaFutures Working Group.

Run over two years, PharmaFutures 5 analyses key trends that are reshaping the reimbursement landscape for medicines around the world. With greater use of data, more patient involvement and a focus on improving patient outcomes with limited resources, payers are redefining the value that medicines bring to health systems. PharmaFutures 5 argues for a new approach to drug research, licensing and pricing that would introduce more flexibility into the system. This will require unprecedented levels of collaboration among key stakeholders, including pharma, regulators, payers and patients.

Pharmafutures Report: Pharmas New Productivity Challenge Perspectives from Europe

Perspectives from Europe

This latest PharmaFutures report summarises the findings of research and discussions about the European pharmaceuticals markets undertaken between November 2011 and May 2012. Focus is on the relationship between pharmaceutical companies, investors and health systems and the question how to maintain a sustainable pharmaceutical industry in Europe.

PharmaFutures is a multi-year, investor-led dialogue between the pharmaceutical industry and its investors about how to manage a rapidly-changing operating environment to deliver long-term value both to society and to shareholders. The project was initiated in 2004 as a scenario-planning exercise and has evolved to a more practically oriented, solutions-focused exploration of the link between sustainable pharmaceutical business models and global health outcomes.

Industry participants are Janssen, GSK, Novo Nordisk and Shire. Other stakeholders include NICE, OECD, the European Commission, JP Morgan, USS, Robeco and Fidelity.

Our EMEA Group Company Chairman, Jane Griffiths, is a Core Group member of the PharmaFutures initiative.

Download the report

If trust between payers and pharma does not improve, further pricing pressures could lead to a genericised standard of care, which, if taken to extremes could lead to a collapse in pricing for many branded pharmaceutical products. If this were to happen, the risk is that industry would be likely to retreat from Europe, closing more R&D and manufacturing sites and diminishing its contribution to Europe’s position as a global research centre. There are already signs of pharma disenchantment with Europe, evidenced by R&D closures and ambivalence about whether markets will sustain new products. Investors, already concerned about the high proportion of current sales facing generic erosion in the next few years, will be concerned about the prospects for growth in these stocks, especially as some consider what happens in Europe to be a precursor to what may happen in other markets. Over time, this downward spiral could have very damaging impacts on the development of new treatments for unmet need: neurodegenerative therapies; antimicrobials; diseases of the developing world; and some long-term conditions.” - A quote from PharmaFutures 2012.

 

Report archive